[HTML][HTML] Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression
J Zhu, Z Zou, P Nie, X Kou, B Wu, S Wang, Z Song… - Cell death & …, 2016 - nature.com
Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
[HTML][HTML] Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression
J Zhu, Z Zou, P Nie, X Kou, B Wu, S Wang… - Cell Death & …, 2016 - ncbi.nlm.nih.gov
Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
[PDF][PDF] Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression
J Zhu, Z Zou, P Nie, X Kou, B Wu, S Wang… - Cell Death and …, 2016 - cyberleninka.org
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by
increasing NR5A2 and CREB1 expression Page 1 OPEN Downregulation of microRNA-27b-3p …
increasing NR5A2 and CREB1 expression Page 1 OPEN Downregulation of microRNA-27b-3p …
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression
J Zhu, Z Zou, P Nie, X Kou, B Wu, S Wang… - Cell Death and …, 2016 - search.proquest.com
Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
J Zhu, Z Zou, P Nie, X Kou, B Wu, S Wang… - Cell Death & …, 2016 - europepmc.org
Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression
J Zhu, Z Zou, P Nie, X Kou, B Wu… - Cell death & …, 2016 - pubmed.ncbi.nlm.nih.gov
Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …
receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those …